Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors

Autor:	Steve Biko Otieno, Syed Nasir, Alva Weir, Robert Johnson
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Diseases of the blood and blood-forming organs RC633-647.5
Zdroj:	Case Reports in Hematology, Vol 2020 (2020)
Druh dokumentu:	article
ISSN:	2090-6560 2090-6579
DOI:	10.1155/2020/8821415
Popis:	Patients with relapsed and refractory multiple myeloma have a poor prognosis. The mitogen-activated protein kinase (MAPK) pathway has been implicated in the pathogenesis of multiple myeloma. Several mutations in this pathway can lead to its constitutive activation leading to oncogenesis. One such mutation is BRAFV600E which is a therapeutic target in the treatment of melanoma, lung cancer, colon cancer, thyroid cancer, and hairy cell leukemia. BRAFV600E-directed therapy currently does not have approval in multiple myeloma. It has been proposed that this mutation leads to proteasome inhibitor resistance. About 4–10% of multiple myeloma cases harbor the BRAFV600E mutation. Herein, we report a case of a patient with relapsed and refractory multiple myeloma who had a progression-free survival (PFS) of 8.5 months on BRAF-targeted therapy.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/3d1e7864c33344de9a467005f3b14510 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.